{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:12:43Z","timestamp":1793308363953,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.esmogo.2026.100307","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T22:14:23Z","timestamp":1771366463000},"page":"100307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Readministration of nivolumab for patients with advanced gastric cancer: a case series"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4548-4109","authenticated-orcid":false,"given":"H.","family":"Kodama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8018-0077","authenticated-orcid":false,"given":"Y.","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5090-9771","authenticated-orcid":false,"given":"K.","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7521-1596","authenticated-orcid":false,"given":"T.","family":"Masuishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kadowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3761-6971","authenticated-orcid":false,"given":"M.","family":"Tajika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmogo.2026.100307_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.esmogo.2026.100307_bib2","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1093\/oncolo\/oyab069","article-title":"Clinical progress in inoperable or recurrent advanced gastric cancer treatment from 1004 single institute experiences between 2007 and 2018","volume":"27","author":"Nakayama","year":"2022","journal-title":"Oncologist"},{"issue":"10111","key":"10.1016\/j.esmogo.2026.100307_bib3","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.esmogo.2026.100307_bib4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10294","key":"10.1016\/j.esmogo.2026.100307_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.esmogo.2026.100307_bib6","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.esmogo.2026.100307_bib7","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","article-title":"Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Shitara","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmogo.2026.100307_bib8","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s10120-016-0670-9","article-title":"Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes","volume":"20","author":"Nishimura","year":"2017","journal-title":"Gastric Cancer"},{"issue":"4","key":"10.1016\/j.esmogo.2026.100307_bib9","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00280-016-3138-z","article-title":"Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer","volume":"78","author":"Kawakami","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.esmogo.2026.100307_bib10","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s10120-017-0759-9","article-title":"Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer","volume":"21","author":"Makiyama","year":"2018","journal-title":"Gastric Cancer"},{"issue":"9","key":"10.1016\/j.esmogo.2026.100307_bib11","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s11912-022-01241-z","article-title":"Immune checkpoint inhibitor rechallenge and resumption: a systematic review","volume":"24","author":"Plazy","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.esmogo.2026.100307_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103434","article-title":"Rechallenge of immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"165","author":"Inno","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.esmogo.2026.100307_bib13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S2468-1253(20)30396-4","article-title":"Safety and activity of trifluridine\/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial","volume":"6","author":"Kawazoe","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.esmogo.2026.100307_bib14","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/ijc.34652","article-title":"Ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab-based therapy","volume":"153","author":"Goetze","year":"2023","journal-title":"Int J Cancer"},{"issue":"suppl 2","key":"10.1016\/j.esmogo.2026.100307_bib15","doi-asserted-by":"crossref","first-page":"S1317","DOI":"10.1016\/j.annonc.2023.10.077","article-title":"The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus irinotecan with irinotecan in the third or later line treatment beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial)","volume":"34","author":"Kadowaki","year":"2023","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.esmogo.2026.100307_bib16","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/COC.0000000000000835","article-title":"Clinical impact of oral intake in second-line or third-line chemotherapy for 589 patients with advanced gastric cancer: a retrospective cohort study","volume":"44","author":"Ogata","year":"2021","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.esmogo.2026.100307_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2019.102816","article-title":"Current opinions in immune checkpoint inhibitors rechallenge in solid cancers","volume":"144","author":"Gobbini","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"10.1016\/j.esmogo.2026.100307_bib18","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/0277-5379(87)90452-4","article-title":"Reinduction chemotherapy in small cell lung cancer","volume":"23","author":"Giaccone","year":"1987","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"15","key":"10.1016\/j.esmogo.2026.100307_bib19","doi-asserted-by":"crossref","first-page":"OF1","DOI":"10.1158\/1078-0432.CCR-22-0602","article-title":"Nivolumab retreatment in non-small cell lung cancer patients who responded to prior immune checkpoint inhibitors and had ICI-free intervals (WJOG9616L)","volume":"28","author":"Akamatsu","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100307_bib20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10120-021-01237-x","article-title":"Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08)","volume":"25","author":"Takahashi","year":"2022","journal-title":"Gastric Cancer"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819826000075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819826000075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T15:05:50Z","timestamp":1775315150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819826000075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":20,"alternative-id":["S2949819826000075"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2026.100307","relation":{},"ISSN":["2949-8198"],"issn-type":[{"value":"2949-8198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Readministration of nivolumab for patients with advanced gastric cancer: a case series","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2026.100307","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100307"}}